A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

NCT05473910 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

AML
Myelodysplastic Syndromes
ALL, Adult

Interventions

DRUG: SOC + TSC-100
DRUG: SOC + TSC-101
OTHER: Control

Sponsor

TScan Therapeutics, Inc.